Ruffer LLP Purchases New Stake in Exelixis, Inc. (NASDAQ:EXEL)

Ruffer LLP acquired a new position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 110,757 shares of the biotechnology company's stock, valued at approximately $3,688,000.

A number of other institutional investors also recently modified their holdings of EXEL. USA Financial Formulas bought a new position in Exelixis in the fourth quarter valued at approximately $32,000. Principal Securities Inc. raised its position in Exelixis by 62.8% during the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 373 shares in the last quarter. Kestra Investment Management LLC acquired a new stake in Exelixis in the fourth quarter valued at $39,000. Brooklyn Investment Group bought a new stake in shares of Exelixis in the 3rd quarter valued at about $42,000. Finally, UMB Bank n.a. lifted its stake in Exelixis by 68.4% in the 4th quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company's stock valued at $45,000 after purchasing an additional 553 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Exelixis

In other news, EVP Patrick J. Haley sold 10,000 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $38.80, for a total transaction of $388,000.00. Following the transaction, the executive vice president now owns 341,028 shares of the company's stock, valued at $13,231,886.40. This represents a 2.85 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Bob Oliver sold 18,647 shares of the stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $37.25, for a total value of $694,600.75. Following the completion of the transaction, the director now owns 33,514 shares in the company, valued at approximately $1,248,396.50. The trade was a 35.75 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 140,343 shares of company stock valued at $5,177,234. 2.85% of the stock is currently owned by insiders.

Remove Ads

Analyst Ratings Changes

Several research firms have issued reports on EXEL. Piper Sandler upped their price objective on Exelixis from $37.00 to $38.00 and gave the company an "overweight" rating in a research note on Wednesday, February 12th. Oppenheimer lowered shares of Exelixis from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $41.00 to $33.00 in a research report on Friday, January 24th. Brookline Capital Management initiated coverage on Exelixis in a report on Monday, December 23rd. They set a "buy" rating for the company. Morgan Stanley raised shares of Exelixis from an "equal weight" rating to an "overweight" rating and raised their price target for the stock from $30.00 to $40.00 in a research report on Monday, January 27th. Finally, Stifel Nicolaus raised their target price on shares of Exelixis from $30.00 to $36.00 and gave the stock a "hold" rating in a report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Exelixis presently has a consensus rating of "Moderate Buy" and a consensus price target of $37.59.

Exelixis Stock Down 1.1 %

Exelixis stock traded down $0.40 during trading hours on Thursday, hitting $36.80. The stock had a trading volume of 2,418,387 shares, compared to its average volume of 2,087,266. The business's 50 day simple moving average is $35.25 and its 200-day simple moving average is $32.33. Exelixis, Inc. has a one year low of $20.14 and a one year high of $40.02. The stock has a market cap of $10.30 billion, a price-to-earnings ratio of 20.79, a P/E/G ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Research analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.